Health Technology · Pharmaceuticals: Major · NSE: SUVEN · data 2026-10-09

Suven Life Sciences Limited

Health check: Weak (1.8/10 on quality, valuation vs sector, growth and momentum).

Open full analysis — chart, results, balance sheet, red flags →

Key figures

Price

₹282.75

Market cap

₹8,155 cr

P/E

—

P/B

—

ROE

-78.8%

ROCE

-80.8%

Debt / equity

0.03

Dividend yield

0.00%

1-year return

40.7%

52-week high

₹403.35

52-week low

₹124.11

Operating margin

-4228.1%

Growth

Revenue (last 12 months)	₹9 cr
Net profit (last 12 months)	₹-352 cr
Sales growth, 3 years (yearly)	-19.3%
Profit growth, 3 years (yearly)	—

Similar companies

Procter & Gamble Health Ltd. (PGHL) · Sanofi Consumer Healthcare India Limited (SANOFICONR) · Aarti Pharmalabs Limited (AARTIPHARM) · Morepen Laboratories Limited (MOREPENLAB) · Bliss GVS Pharma Limited (BLISSGVS)

The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.

Open SUVEN in NSE Scanner →